Search research articles
Contact Us
Filters
Showing results (31-40 of 94) with videos related to
Page
of 10
Sort By:
The Annals of Pharmacotherapy
|
April 20, 2000
Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient
L Piroth, M Grappin, C Sgro, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 3, 2000
Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy
L Piroth, M Grappin, M Buisson, et al.
Journal of Virology
|
June 14, 2000
Epstein-Barr virus EB2 protein exports unspliced RNA via a Crm-1-independent pathway
G Farjot, M Buisson, M Duc Dodon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 1, 1996
Vertebral osteomyelitis due to Capnocytophaga species in immunocompetent patients: report of two cases and review
M Duong, J F Besancenot, C Neuwirth, et al.
Clinical and Vaccine Immunology : CVI
|
April 28, 2012
Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status
J Lupo, R Germi, T Semenova, et al.
The Journal of Antimicrobial Chemotherapy
|
March 1, 1997
In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits
P Chavanet, M Duong, M Buisson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 5, 2001
Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: a potential interest in clinical practice
M Grappin, L Piroth, E Kohli, et al.
Journal of Virology
|
December 1, 1989
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R
M Buisson, E Manet, M C Trescol-Biemont, et al.
The Journal of General Virology
|
February 1, 1994
Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection
M Buisson, P Morand, O Genoulaz, et al.
Leukemia
|
February 20, 1999
Development of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type
M Buisson, P Morand, M Peoc'h, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 94) with videos related to
Sort By:
Page
of 10
The Annals of Pharmacotherapy
|
April 20, 2000
Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient
L Piroth, M Grappin, C Sgro, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 3, 2000
Hepatitis B virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy
L Piroth, M Grappin, M Buisson, et al.
Journal of Virology
|
June 14, 2000
Epstein-Barr virus EB2 protein exports unspliced RNA via a Crm-1-independent pathway
G Farjot, M Buisson, M Duc Dodon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 1, 1996
Vertebral osteomyelitis due to Capnocytophaga species in immunocompetent patients: report of two cases and review
M Duong, J F Besancenot, C Neuwirth, et al.
Clinical and Vaccine Immunology : CVI
|
April 28, 2012
Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status
J Lupo, R Germi, T Semenova, et al.
The Journal of Antimicrobial Chemotherapy
|
March 1, 1997
In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits
P Chavanet, M Duong, M Buisson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 5, 2001
Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: a potential interest in clinical practice
M Grappin, L Piroth, E Kohli, et al.
Journal of Virology
|
December 1, 1989
The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R
M Buisson, E Manet, M C Trescol-Biemont, et al.
The Journal of General Virology
|
February 1, 1994
Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection
M Buisson, P Morand, O Genoulaz, et al.
Leukemia
|
February 20, 1999
Development of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type
M Buisson, P Morand, M Peoc'h, et al.
Page
of 10